

INVITATION TO PRESENTATION OF SEDANA MEDICAL'S INTERIM REPORT FOR THE SECOND QUARTER 2026

Sedana Medical AB (publ) plans to present its interim report for the second quarter of 2026 on Friday July 17 at 13:30 CET.

According to the financial calendar, Sedana Medical plans to publish the interim report for the second quarter 2026 on Friday July 17 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes Doll will present the report in English together with Mikael Haag, CFO, and Peter Sackey, CMO, as well as answer questions.

Date: Friday, July 17, 2026

Time (CET): 13:30

More info and link to the audiocast: <https://www.finwire.tv/webcast/sedana-medical/q2-2026/>

If you wish to participate via teleconference: +46 8 5052 0017. Meeting ID: 966 6000 2846 followed by #.

Welcome!

For additional information, please contact:

Johannes Doll, CEO, +46 (0)76 303 66 66

Mikael Haag, CFO, +46 (0)79 583 42 59

ir@sedanamedical.com

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.

For additional information, please contact:

Johannes Doll, CEO, +46 (0)76 303 66 66
Mikael Haag, CFO, +46 (0)79 583 42 59
ir@sedanamedical.com

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.

Attachments

Invitation to presentation of Sedana Medical's interim report for the second quarter 2026